The DOI matches its Crossref record; 314 of the 314 references it cites were found in a registry or an index.
TNF ligands and receptors – a matter of life and death
Open accessAbstract
It had been known for some time that tumour masses which had become contaminated by a bacterial infection would on occasion regress and disappear. It was thought that the bacteria were releasing a factor which would make the tumour necrotic and whither. This factor was termed tumour necrosis factor (TNF) (Old, 1985). It was not until more recent advances in immunology that it became clear that antigens from the bacterial invader (notably lipopolysaccharide LPS) were causing the release of the patient's own TNF which could cause the tumour regression. The hunt was on to isolate this TNF which could be used as a magic therapy to control cancer cell growth and persistence, plus enhance the academic understanding of the ways by which a cell could die. It was discovered that TNF and lymphotoxin (LT) were products from macrophages and lymphocytes that were capable of lysing many cell types including some tumour cells (Carswell et al., 1975; Granger et al., 1969). TNF was also found to be identical to the protein cachectin, which was known to be involved in the fever and muscle wastage seen in cancer patients (Beutler et al., 1985). Hence, the role TNF played in a range of physiological actions was important and the hunt was on to identify TNF and related molecules such as LT. Modern techniques have since allowed the isolation, characterization and cloning of the genes for TNF which is structurally related to LT plus an expanding family of TNF-like ligands (Table 1). These cytokine molecules include ligands such as Fas, CD40 and RANK which cause wide-ranging long-term cellular activities in cells such as differentiation, proliferation or death. Evolution has created this TNF superfamily of cytokines to control and manipulate the immune system, modulating processes such as haematopoiesis, antibody production, or short- and long-term immunity. It is only through its quirky tumour-killing characteristic that TNF cytokine was first identified and may still hold the key to effective tumour therapy. As the majority of information has been gained about TNF and it is the archetypal cytokine of the superfamily, displaying the greatest range of cellular actions, this review will focus on the molecular aspects and biological role of TNF signalling. Biochemically isolated in 1984, TNF has since been found to be a pleiotropic agent produced mostly by activated macrophages and monocytes, but also by many other cell types including B lymphocytes, T lymphocytes and fibroblasts. It is expressed as a 26 kDa transmembrane protein that can be cleaved by the metalloprotease TNF-α-converting enzyme (TACE) to release a 17 kDa soluble TNF form (Idriss & Naismith, 2000). TNF has also referred to as TNFα, cachectin or differentiation inducing factor (DIF) (Aggarwal, 2000). Its superfamily of nearly 20 different homologues including TNF-β (lymphotoxin-α), lymphotoxin-β, and other more specific ligands such as RANKL and TRAIL which are involved more particularly in bone tissue and lymphocyte processes. All the TNF receptor superfamily of ligands are thought form non-covalently-bound homo-trimers which are capable of becoming a secreted form (Figure 1). These TNF ligand are primarily designed for cell – cell contact transfer of signalling information between neighbouring cells, but cleavage into their soluble forms may allow more dispersed cytokine effects. TNF as well as causing necrotic cell death may also cause apoptotic cell death, cellular proliferation, differentiation, inflammation, tumourigenesis, and viral replication (Figure 2). TNF's primary role is in the regulation of immune cells, but is known to be heavily involved in pathogenic disorders such as rheumatoid arthritis, asthma, septic shock, irritable bowel disorder, haemorrhagic fever and cachexia (Locksley et al., 2001). TNF superfamily ligand-receptor interactions. TNF receptor-mediated cellular responses. Just as modern molecular techniques have identified a superfamily of TNF-like cytokine ligands, their receptor molecules consist of a superfamily of proteins that can be activated by one or more ligands (Table 2). TNF receptors are an family of proteins that consist of, to date, at least 27 members characterized by their repeated cysteine-rich extracellular sequence homology, and include LT receptor, Fas, CD40, the low affinity nerve growth factor receptor, TRAIL receptors, RANK and death or decoy receptors (Darnay & Aggarwal, 1999). Many of these members go by multiple names and are activated by specific ligands, however TNF only has the ability to bind two of these receptors which are also activated by LTα. TNF ligand achieves all its different cellular and pathological effects by its binding to either the TNFR1 or TNFR2 receptor subtype. They are single transmembrane glycoproteins with 28% homology mostly in their extracellular domain with both containing four tandemly repeated cysteine rich motifs. Their intracellular sequences are largely unrelated with almost no homolo
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–314 of 314
From Vanadis to Atropos: vanadium compounds as pharmacological tools in cell death signalling
Morinville, A., Maysinger, D., & Shaver, A. G. (1998) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(98)01257-7 · Cited by 121
Decoster, E., Vanhaesebroeck, B., Vandenabeele, P., Grooten, J., & Fiers, W. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.31.18473 · Cited by 118
Evaluation of the role of RANK and OPG genes in Paget’s disease of bone
Wuyts, W. A., Wesenbeeck, L. V., Morales-Piga, A. A., Ralston, S. H., Hocking, L. J., Vanhoenacker, F. M. H. M., Westhovens, R., Verbruggen, L., Anderson, D. M., Hughes, A., et al. (2001) · Bone · doi:10.1016/s8756-3282(00)00411-7 · Cited by 117
TR60 and TR80 tumor necrosis factor (TNF)-receptors can independently mediate cytolysis.
Grell, M., Scheurich, P., Meager, A., & Pfizenmaier, K. (1993) · PubMed · Cited by 115
Amrani, Y., Panettieri, R. A., Frossard, N., & Bronner, C. (1996) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/ajrcmb.15.1.8679222 · Cited by 114
Medvedev, A. E., Espevik, T., Ranges, G. E., & Sundan, A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.16.9778 · Cited by 113
A Human Suppressor of c-Jun N-terminal Kinase 1 Activation by Tumor Necrosis Factor α
Jin, D., Teramoto, H., Giam, C., Chun, R. F., Gutkind, J. S., & Jeang, K. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.41.25816 · Cited by 112
Kruppa, G., Thoma, B., Machleidt, T., Wiegmann, K., & Krönke, M. (1992) · The Journal of Immunology · doi:10.4049/jimmunol.148.10.3152 · Cited by 111
Godfrey, R. W., Johnson, W. J., & Hoffstein, S. T. (1987) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(87)90476-1 · Cited by 110
Paleolog, E. M., Delasalle, S., Buurman, W. A., & Feldmann, M. (1994) · Blood · doi:10.1182/blood.v84.8.2578.2578 · Cited by 109
Granger, G. A., SHACKS, S. J., Williams, T. W., & Kolb, W. P. (1969) · Nature · doi:10.1038/2211155a0 · Cited by 109
Müller, G. I., Störz, P., Bourteele, S., Döppler, H. R., Pfizenmaier, K., Mischak, H., Philipp, A., Kaiser, C., & Kölch, W. (1998) · The EMBO Journal · doi:10.1093/emboj/17.3.732 · Cited by 107
CORONEOS, E., Wang, Y., Panuska, J. R., Templeton, D. J., & KESTER, M. A. (1996) · Biochemical Journal · doi:10.1042/bj3160013 · Cited by 106
Amrani, Y., Lazaar, A. L., & Panettieri, R. A. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.4.2128 · Cited by 104
Schütze, S., Nottrott, S., Pfizenmaier, K., & Krönke, M. (1990) · The Journal of Immunology · doi:10.4049/jimmunol.144.7.2604 · Cited by 104
Staurosporine analogues — pharmacological toys or useful antitumour agents?
Gescher, A. J. (2000) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(00)00058-5 · Cited by 103
Fiers, W., Beyaert, R., Boone, E., Cornelis, S., Declercq, W., Decoster, E., Denecker, G., Depuydt, B., VALCK, D. D., Wilde, G. D., et al. (1995) · PubMed · Cited by 102
WANG, B., Kondo, S., Shivji, G. M., Fujisawa, H., Mak, T. W., & Sauder, D. N. (1996) · Immunology · doi:10.1111/j.1365-2567.1996.tb00016.x · Cited by 101
Castellino, A. M., Parker, G. J., Boronenkov, I. V., Anderson, R. A., & Chao, M. V. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.9.5861 · Cited by 100
Tumor necrosis factor induces a selective shedding of its p75 receptor from human neutrophils.
Porteu, F., & Hiéblot, C. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)42018-7 · Cited by 96
Digel, W., Porzsolt, F., Schmid, M., Herrmann, F., Lesslauer, W., & Brockhaus, M. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115769 · Cited by 96
Brinkman, B. M. N., Telliez, J., Schievella, A. R., Lin, L., & Goldfeld, A. E. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.43.30882 · Cited by 95
Bolger, A. P., & Anker, S. D. (2000) · Drugs · doi:10.2165/00003495-200060060-00002 · Cited by 93
Baxter, G. T., Kuo, R. C., Jupp, O. J., Vandenabeele, P., & MacEwan, D. J. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.14.9539 · Cited by 93
Self-citationBird, T. A., Kyriakis, J. M., Tyshler, L., Gayle, M. A., Milne, A., & Virca, G. D. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)31771-x · Cited by 91
Darnay, B. G., & Aggarwal, B. B. (1999) · Annals of the Rheumatic Diseases · doi:10.1136/ard.58.2008.i2 · Cited by 84
Sethi, J. K., Xu, H., Uysal, K. T., Wiesbrock, S. M., Scheja, L., & Hotamışlıgil, G. S. (2000) · FEBS Letters · doi:10.1016/s0014-5793(00)01250-3 · Cited by 83
Lægreid, A., Medvedev, A. E., Nonstad, U., Bombara, M. P., Ranges, G. E., Sundan, A., & Espevik, T. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)37355-6 · Cited by 81
Jupp, O. J., McFarlane, S. M., Anderson, H. M., LITTLEJOHN, A. F., MOHAMED, A. A. A., MacKAY, R. H., Vandenabeele, P., & MacEwan, D. J. (2001) · Biochemical Journal · doi:10.1042/0264-6021:3590525 · Cited by 80
Self-citationAmrani, Y., Martinet, N., & Bronner, C. (1995) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1995.tb14896.x · Cited by 79
Suffys, P. N., Beyaert, R., VALCK, D. D., Vanhaesebroeck, B., Roy, F. M. V., & Fiers, W. (1991) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1991.tb15727.x · Cited by 78
Lint, J. V., Agostinis, P., Vandevoorde, V., Haegeman, G., Fiers, W., Merlevede, W. J., & Vandenheede, J. R. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)35695-3 · Cited by 77
Estrov, Z. E., Manna, S. K., Harris, D., Van, Q., Estey, E. H., Kantarjian, H. M., Talpaz, M., & Aggarwal, B. B. (1999) · Blood · doi:10.1182/blood.v94.8.2844.420k43_2844_2853 · Cited by 77
Adam-Klages, S., Schwandner, R., Adam, D., Kreder, D., Bernardo, K., & Krönke, M. (1998) · Journal of Leukocyte Biology · doi:10.1002/jlb.63.6.678 · Cited by 77
Ras signaling in tumor necrosis factor‐induced apoptosis.
Trent, J. C., McConkey, D. J., Loughlin, S. M., Harbison, M. T., Fernandez, A., & Ananthaswamy, H. N. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00827.x · Cited by 76
Lin, W., & Chen, B. C. (1998) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0702219 · Cited by 74
Parris, J. R. M., Cobban, H. J., LITTLEJOHN, A. F., MacEwan, D. J., & Nixon, G. F. (1999) · The Journal of Physiology · doi:10.1111/j.1469-7793.1999.0561p.x · Cited by 74
Self-citationJohannes, F., Horn, J., Link, G., Haas, E., Siemienski, K., Wajant, H., & Pfizenmaier, K. (1998) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.1998.2570047.x · Cited by 72
Lazdins, J. K., Grell, M., Walker, M. R., Woods-Cook, K., Scheurich, P., & Pfizenmaier, K. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.185.1.81 · Cited by 71
Pennica, D., Kohr, W. J., FENDLY, B. M., Shire, S. J., Raab, H. E., Borchardt, P. E., Lewis, M., & Goeddel, D. V. (1992) · Biochemistry · doi:10.1021/bi00119a023 · Cited by 71
Anti-TNF Therapy for Rheumatoid Arthritis and Other Inflammatory Diseases
Taylor, P. C. (2001) · Molecular Biotechnology · doi:10.1385/mb:19:2:153 · Cited by 71
Identification of Grb2 As a Novel Binding Partner of Tumor Necrosis Factor (TNF) Receptor I
Hildt, E., & Oess, S. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.11.1707 · Cited by 70
Manna, S. K., & Aggarwal, B. B. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.50.33333 · Cited by 70
c-Jun Is a Downstream Target for Ceramide-activated Protein Phosphatase in A431 Cells
Reyes, J. G., González, I., Delgado, P. S., González, I., Aguiar, J. Q., Estévez, F., Fanjul, L. F., & de Galarreta, C. M. R. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.35.21375 · Cited by 68
Caspase-Mediated Inhibition of Human Cytosolic Phospholipase A2 During Apoptosis
Adam‐Klages, S., Schwandner, R., Lüschen, S., Ussat, S., Kreder, D., & Krönke, M. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.10.5687 · Cited by 68
Pennica, D., Lam, V. T., Mize, N. K., Weber, R. F., Lewis, M., FENDLY, B. M., Lipari, M. T., & Goeddel, D. V. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)36813-9 · Cited by 67
TNF receptor p55 controls early acute graft-versus-host disease
Speiser, D. E., Bachmann, M., Frick, T. W., McKall-Faienza, K., Griffiths, E. K., Pfeffer, K., Mak, T. W., & Ohashi, P. S. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.11.5185 · Cited by 67
Hernández‐Muñoz, I., de la Torre, P., Sánchez-Alcázar, J. A., García‐Ruíz, I., de Santiago, E., Muñoz-Yagüe, M. T., & Solís-Herruzo, J. (1997) · Gastroenterology · doi:10.1053/gast.1997.v113.pm9247485 · Cited by 66
Couriel, D. R., Hicks, K. L., Giralt, S., & Champlin, R. E. (2000) · Current Opinion in Oncology · doi:10.1097/00001622-200011000-00011 · Cited by 65
Anti-TNF agents in Crohn’s disease
Assche, G. V., & Rutgeerts, P. J. (2000) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.9.1.103 · Cited by 64
Lucas, R., Garcia, I., Donati, Y. R. A., Hribar, M., Mandriota, S. J., Giroud, C., Buurman, W. A., Fransen, L., Suter, P. M., Núñez, G., et al. (1998) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199811)28:11<3577::aid-immu3577>3.0.co;2-# · Cited by 62
Respective role of TNF receptors in the development of experimental cerebral malaria
Lucas, R., Lou, J.-N., Juillard, P., Moore, M. W., Bluethmann, H., & Grau, G. E. (1997) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(96)00185-3 · Cited by 61
Kalb, A., Bluethmann, H., Moore, M. W., & Lesslauer, W. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.45.28097 · Cited by 60
Lee, J. Y., Hannun, Y. A., & Obeid, L. M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m000170200 · Cited by 59
Yan, F., & Polk, D. B. (2001) · PubMed · Cited by 59
Amrani, Y., Lazaar, A. L., Hoffman, R. K., Amin, K., Ousmer, S., & Panettieri, R. A. (2000) · Molecular Pharmacology · doi:10.1124/mol.58.1.237 · Cited by 59
Cottin, V., Linden, A. V., & Riches, D. W. H. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.46.32975 · Cited by 58
The divergent role of tumor necrosis factor receptors in infectious diseases
Schlüter, D., & Deckert, M. (2000) · Microbes and Infection · doi:10.1016/s1286-4579(00)01282-x · Cited by 57
Soluble cytokine receptors: novel immunotherapeutic agents
Fernandez-Botrán, R. (2000) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.9.3.497 · Cited by 56
Dhawan, S., Singh, S., & Aggarwal, B. B. (1997) · European Journal of Immunology · doi:10.1002/eji.1830270909 · Cited by 55
Elevated cPLA2 levels as a mechanism by which the p70 TNF and p75 NGF receptors enhance apoptosis
MacEwan, D. J. (1996) · FEBS Letters · doi:10.1016/0014-5793(95)01495-0 · Cited by 52
Self-citationWu, Y., Jiang, X. R., Lillington, D., Allen, P. D., Newland, A. C., & Kelsey, S. M. (1998) · PubMed · Cited by 51
Kim, B.-C., Lee, M.-N., Kim, J.-Y., Lee, S.-S., Chang, J.-D., Kim, S.-S., Lee, S.-Y., & Kim, J.-H. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.34.24372 · Cited by 50
BRE: a modulator of TNF‐α action
Gu, C., Castellino, A. M., Chan, J. Y., & Chao, M. V. (1998) · The FASEB Journal · doi:10.1096/fasebj.12.12.1101 · Cited by 49
Vercammen, D., Vandenabeele, P., Declercq, W., de Craen, M. V., Grooten, J., & Fiers, W. C. (1995) · Cytokine · doi:10.1006/cyto.1995.0063 · Cited by 48
THE ROLE OF TUMOUR NECROSIS FACTOR-α IN THE PATHOGENESIS OF COMPLICATED FALCIPARUM MALARIA
Odeh, M. (2001) · Cytokine · doi:10.1006/cyto.2001.0845 · Cited by 47
Díaz, F., & Bourguignon, L. (2000) · Cell Calcium · doi:10.1054/ceca.2000.0126 · Cited by 47
Continuous Autotropic Signaling by Membrane-expressed Tumor Necrosis Factor
Haas, E., Grell, M., Wajant, H., & Scheurich, P. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.25.18107 · Cited by 46
Yanaga, F., Abe, M., Koga, T., & Hirata, M. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42738-x · Cited by 45
Boone, E., Vandevoorde, V., Wilde, G. D., & Haegeman, G. (1998) · FEBS Letters · doi:10.1016/s0014-5793(98)01567-1 · Cited by 45
Laouar, A., Glesne, D. A., & Huberman, E. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.33.23526 · Cited by 45
Failure to Activate Cytosolic Phospholipase A2 Causes TNF Resistance in Human Leukemic Cells
Wu, Y., Jiang, X., Newland, A. C., & Kelsey, S. M. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.12.5929 · Cited by 43
Bonizzi, G., Piette, J. G., Schoonbroodt, S., Merville, M., & Bours, V. (1999) · Biochemical Pharmacology · doi:10.1016/s0006-2952(98)00353-0 · Cited by 43
Chronic myelogenous leukaemia – new therapeutic principles
O'Dwyer, M. E., & Druker, B. J. (2001) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2001.00823.x · Cited by 43
Squier, M. K. T., & Cohen, J. (1996) · PubMed · Cited by 42
Tumor Necrosis Factor Receptor 2 Plays a Minor Role for Mycobacterial Immunity
Jacobs, M., Brown, N., Allie, N., Chetty, K., & Ryffel, B. (2000) · Pathobiology · doi:10.1159/000028116 · Cited by 40
Serine phosphorylation of p60 tumor necrosis factor receptor by PKC-δ in TNF-α-activated neutrophils
Kilpatrick, L. E., Song, Y., Rossi, M. W., & Korchak, H. M. (2000) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.2000.279.6.c2011 · Cited by 39
Tótpál, K., Agarwal, S., & Aggarwal, B. B. (1992) · PubMed · Cited by 37
VALCK, D. D., Vercammen, D., Fiers, W., & Beyaert, R. (1998) · Journal of Cellular Biochemistry · Cited by 36
Pharmacological Modulation of Cytokine Action and Production through Signaling Pathways
Young, P. R. (1998) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(98)00011-2 · Cited by 35
Azotemia, TNFα, and LPS prime the human neutrophil oxidative burst by distinct mechanisms
McLeish, K. R., Klein, J. B., Lederer, E. D., Head, K. Z., & Ward, R. A. (1996) · Kidney International · doi:10.1038/ki.1996.330 · Cited by 34
TNF inhibits insulin induced STAT5 activation in differentiated mouse muscle cells pmi28
Störz, P., Döppler, H. R., Wernig, A., Pfizenmaier, K., & Müller, G. I. (1998) · FEBS Letters · doi:10.1016/s0014-5793(98)01421-5 · Cited by 33
Cleavage of Human Cytosolic Phospholipase A2by Caspase-1 (ICE) and Caspase-8 (FLICE)
Lüschen, S., Ussat, S., Krönke, M., & Adam‐Klages, S. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.9754 · Cited by 33
Beyaert, R., Heyninck, K., VALCK, D. D., Boeykens, F., Roy, F. M. V., & Fiers, W. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.151.1.291 · Cited by 32
Thrombin-Induced Activation of RhoA in Platelet Shape Change
Bodie, S. L., Ford, I., Greaves, M., & Nixon, G. F. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.5547 · Cited by 32
Leeuwenberg, J. F. M., van Tits, L. J. H., Jeunhomme, T. M. A. A., & Buurman, W. A. (1995) · Cytokine · doi:10.1006/cyto.1995.0062 · Cited by 32
Reithmann, C., & Werdan, K. (1994) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/bf00169834 · Cited by 31
Kang, J. H., Shin, I., & Han, J. (1998) · Experimental & Molecular Medicine · doi:10.1038/emm.1998.3 · Cited by 31
Kong, S. K., Fung, K., Choy, Y. M., & Lee, C. Y. (2009) · Oncology · doi:10.1159/000227662 · Cited by 29
Calcium Signalling and the Regulation of Apoptosis
Pörn-Ares, M. I., Ares, M. P. S., & Orrenius, S. (1998) · Toxicology in Vitro · doi:10.1016/s0887-2333(98)00032-0 · Cited by 28
Børset, M., Medvedev, A. E., Sundan, A., & Espevik, T. (1996) · Cytokine · doi:10.1006/cyto.1996.0059 · Cited by 27
Darnay, B. G., Reddy, S. A. G., & Aggarwal, B. B. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)32074-4 · Cited by 26
Scherzer, J. A., Lin, Y., McLeish, K. R., & Klein, J. B. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.2.913 · Cited by 26
McFarlane, S. M., Jupp, O. J., Cobban, H. J., Hunter, I., Anderson, H. M., Vandenabeele, P., Nixon, G. F., & MacEwan, D. J. (2001) · Biochemical Pharmacology · doi:10.1016/s0006-2952(01)00530-5 · Cited by 26
Self-citationConway, A.-M. (2000) · Cellular Signalling · doi:10.1016/s0898-6568(00)00119-4 · Cited by 22
Doman, R. K., Perez, M., & Donato, N. J. (1999) · Journal of Interferon & Cytokine Research · doi:10.1089/107999099314199 · Cited by 22
Fong, C. W., Zhang, Y., Neo, S. Y., & Lin, S. (2000) · Biochemical Journal · doi:10.1042/bj3520747 · Cited by 22
Mishra, S., Mathur, R., & Hamburger, A. W. (1994) · PubMed · Cited by 21
Tyrosine kinase inhibitors in the treatment of chronic myeloid leukaemia: so far so good?
Drummond, M. W., & Holyoake, T. L. (2001) · Blood Reviews · doi:10.1054/blre.2001.0152 · Cited by 20
Chang, N. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.1909 · Cited by 20
Pollock, V. P., Lofthouse, E., Jupp, O. J., Gauld, S. B., Anderson, H., & MacEwan, D. J. (2000) · Molecular and Cellular Biochemistry · doi:10.1023/a:1007066409645 · Cited by 18
Self-citationDarnay, B. G., Singh, S., & Aggarwal, B. B. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)00251-2 · Cited by 18
Darnay, B. G., & Aggarwal, B. B. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)00652-2 · Cited by 18
Declercq, W., Vandenabeele, P., & Fiers, W. (1995) · Cytokine · doi:10.1006/cyto.1995.0082 · Cited by 18
Denecker, G., Vandenabeele, P., Grooten, J., Penning, L. C., Declercq, W., Beyaert, R., Buurman, W. A., & Fiers, W. (1997) · Cytokine · doi:10.1006/cyto.1997.0218 · Cited by 18
Rosado, J. A., Rosenzweig, I., Harding, S., & Sage, S. O. (2001) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.2001.280.6.c1636 · Cited by 18
Barber, S. A., Perera, P., McNally, R., & Vogel, S. N. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.3.1404 · Cited by 17
Branellec, D., de Crémoux, P., Barreau, P., Calvo, F. M., & Chouaı̈b, S. (1992) · European Journal of Immunology · doi:10.1002/eji.1830220413 · Cited by 14
Modulated kinase activities in cells undergoing tumour necrosis factor‐induced apoptotic cell death
Helms, M. J., MOHAMED, A. A. A., & MacEwan, D. J. (2001) · FEBS Letters · doi:10.1016/s0014-5793(01)02779-x · Cited by 13
Self-citationMcFarlane, S. M., Anderson, H. M., Tucker, S. J., Jupp, O. J., & McEwan, D. J. (2000) · Molecular and Cellular Biochemistry · doi:10.1023/a:1007189911897 · Cited by 12
Moosmayer, D., Dinkel, A., Gerlach, E., Hessabi, B., Grell, M., Pfizenmaier, K., & Scheurich, P. (1994) · PubMed · Cited by 12
Endothelin-Stimulated Ca2+Mobilization by 3T3-L1 Adipocytes Is Suppressed by Tumor Necrosis Factor-α
Yorek, M. A., Jaipaul, N., Dunlap, J. A., & Bielefeldt, K. (1999) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1998.0982 · Cited by 11
Epstein-Barr virus-dependent lymphoproliferative disease: critical role of IL-6
(2000) · Pure Amsterdam UMC · doi:10.1002/1521-4141(200007)30:7 · Cited by 1
(2001) · doi:10.1002/1098-1128(200103)21:2<129::aid-med1003>3.0.co;2-h
Cited by
Kettenmann, H., Hanisch, U.-K., Noda, M., & Verkhratsky, A. (2011) · Physiological Reviews · doi:10.1152/physrev.00011.2010 · Cited by 3,547
Targeting apoptosis in cancer therapy
Carneiro, B. A., & El-Deiry, W. S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0341-y · Cited by 2,542
Brain Inflammation in Epilepsy: Experimental and Clinical Evidence
Vezzani, A., & Granata, T. (2005) · Epilepsia · doi:10.1111/j.1528-1167.2005.00298.x · Cited by 1,036
Inflammatory Cytokines and Postmyocardial Infarction Remodeling
Nian, M., Lee, P., Khaper, N., & Liu, P. (2004) · Circulation Research · doi:10.1161/01.res.0000130526.20854.fa · Cited by 1,028
Differential Regulation of AMPA Receptor and GABA Receptor Trafficking by Tumor Necrosis Factor-α
Stellwagen, D., Beattie, E. C., Seo, J. Y., & Malenka, R. C. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.4486-04.2005 · Cited by 985
“Cytokines and cytokine receptor materials were from R & D Systems (Minneapolis, MN), except the TNFR2 activating antibodies, which were from Abcam (Cambridge, MA).”
BackgroundInfluential
Metadata
- Authors
- MacEwan, D. J.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2002-02
- Volume
- 135
- Issue
- 4
- Pages
- 855-875
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2025267218
- Cited by
- 391
- References
- 314
- FWCI
- 5.08
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.